Business UpdateApr 23, 2026, 03:48 PM
Regeneron to Offer Free Gene Therapy, Lower Drug Prices in US
AI Summary
Regeneron Pharmaceuticals announced an agreement with the U.S. government to lower prices and increase access to several current and future medicines. The company will offer its newly approved gene therapy, Otarmeni, for free in the U.S. and reduce Medicaid prices for existing drugs based on international benchmarks. Additionally, U.S. prices for future medicines will align with those in other developed countries, and Praluent will be available for direct patient purchase via TrumpRx.gov. This agreement aims to ensure broader patient access while preserving innovation and avoiding future pricing mandates.
Key Highlights
- Regeneron will provide Otarmeni, its recently approved gene therapy for genetic hearing loss, for free in the U.S.
- Regeneron will lower Medicaid prices based on prices in other developed countries.
- U.S. prices for future medicines will be aligned with prices set in a defined group of other countries.
- Praluent will be available for direct patient purchase through TrumpRx.gov.
- Regeneron will not be subject to future pricing mandates and receives three years of tariff relief.